title: Efficacy of conventional and extended intra-mammary treatment of persistent sub-clinical mastitis with cefquinome in lactating dairy cows.
abstract: The objectives of the present study were to evaluate the efficacy of intra-mammary-administered cefquinome for the treatment of sub-clinical mastitis in lactating dairy cows and to determine if extended therapy would enhance treatment efficacy. Seventy-three Holstein dairy cows from a single farm with 150 infected quarters were enrolled in the study. Infected cows were allocated randomly to one of three treatment regimens: (1) conventional (standard) regimen: 75 mg of cefquinome administered three times at 16-h intervals (25 infected cows, 52 intra-mammary infections (IMI)), (2) extended regimen: 75 mg of cefquinome administered six times at 16-h intervals (26 infected cows, 58 IMI) and (3) negative untreated control group (22 cows, 40 IMI). Most IMI were caused by coagulase-negative staphylococci, streptococci other than Streptococcus agalactiae and coliforms. The overall bacteriological cure (BC) rates for sub-clinical IMI were 84.61%, 91.37% and 20% for the conventional, extended and the control groups, respectively, indicating a higher BC rate for the treated groups than the control group (P < 0.001). Significant differences in somatic cell count (SCC) were detected between the treated versus the control group (P < 0.001). No differences, concerning the BC rate or SCC, were observed between the extended and the conventional groups. Although fat and protein percentages increased in the treated groups, there were no significant differences in post-treatment milk production between the groups. Results of this study indicate that cefquinome therapy was effective in reducing SCC and eliminating sub-clinical IMI in lactating dairy cows, but extended therapy did not enhance treatment efficacy.
authors: Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, 14155-6453, Iran. kasravir@yahoo.com
authors: Reza
authors: R
authors: Kasravi
authors: Mahmoud
authors: M
authors: Bolourchi
authors: Nima
authors: N
authors: Farzaneh
authors: Hesam A
authors: HA
authors: Seifi
authors: Abbas
authors: A
authors: Barin
authors: Parviz
authors: P
authors: Hovareshti
authors: Faramarz
authors: F
authors: Gharagozlou
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D058345:Asymptomatic Infections / Q000628:therapy; D002417:Cattle; D002452:Cell Count; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000662:veterinary; D005260:Female; D007271:Injections, Intradermal / Q000662:veterinary*; D007492:Iran; D008321:Mammary Glands, Animal / Q000187:drug effects* / Q000382:microbiology; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000662:veterinary; D013210:Staphylococcus / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000188:drug therapy / Q000662:veterinary; D013291:Streptococcus / Q000302:isolation & purification; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C068212:cefquinome